Zhang Cheng, Liu Jun, Zhong Jiang F, Zhang Xi
Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037 People's Republic of China.
Division of Periodontology, Diagnostic Sciences & Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA USA.
Biomark Res. 2017 Jun 24;5:22. doi: 10.1186/s40364-017-0102-y. eCollection 2017.
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood. After the T cells are expanded and genetically modified, they are reinfused into the patients. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. In this review, we first discuss the structure and evolution of chimeric antigen receptors. We then report on the tools used for production of CAR-T cells. Finally, we address the challenges posed by CAR-T cells.
嵌合抗原受体重定向T细胞（CAR-T细胞）在B细胞恶性肿瘤患者中取得了令人鼓舞的成果，目前正在其他血液系统恶性肿瘤和实体瘤中进行研究。CAR-T细胞由患者或供者血液中的T细胞产生。T细胞经过扩增和基因改造后，再回输到患者体内。然而，为了使这项技术得到广泛应用，仍有许多挑战需要解决。在这篇综述中，我们首先讨论嵌合抗原受体的结构和演变。然后报告用于生产CAR-T细胞的工具。最后，我们阐述CAR-T细胞带来的挑战。
